Regarding T-ALL subtypes, the previously mentioned lncRNAs (i.e., NALT [32], CDKN2B-AS1 [34]), beyond their oncogenic activity, have shown a potential employment as biomarkers, as their expression is upregulated in pediatric T-ALL patients compared to healthy controls. The gene discussed is CDKN2B; the disease is acute lymphoblastic leukemia.